Placebo News and Research RSS Feed - Placebo News and Research

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies led by researchers from the Farncombe Family Digestive Health Research Institute at McMaster University show that transplantation of fecal matter may be a useful tool in the fight against ulcerative colitis (UC). [More]
Gene therapy improves lung function in patients with cystic fibrosis

Gene therapy improves lung function in patients with cystic fibrosis

Gene therapy was shown to provide significant benefits for patients with cystic fibrosis in a recent clinical study published in The Lancet Respiratory Medicine journal. [More]
Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. [More]
Gene therapy for cystic fibrosis shows significant benefit in lung function

Gene therapy for cystic fibrosis shows significant benefit in lung function

For the first time gene therapy for cystic fibrosis has shown a significant benefit in lung function compared with placebo, in a phase 2 randomised trial published in The Lancet Respiratory Medicine journal. The technique replaces the defective gene response for cystic fibrosis by using inhaled molecules of DNA to deliver a normal working copy of the gene to lung cells. [More]
Vitamin B12 supplements offer no benefits for neurological or cognitive function in older people

Vitamin B12 supplements offer no benefits for neurological or cognitive function in older people

Vitamin B12 supplements offer no benefits for neurological or cognitive function in older people with moderate vitamin B12 deficiency, according to a new study published in the American Journal of Clinical Nutrition. [More]
Testosterone, cortisol hormones may destabilise financial markets by making traders take more risks

Testosterone, cortisol hormones may destabilise financial markets by making traders take more risks

The hormones testosterone and cortisol may destabilise financial markets by making traders take more risks, according to a study. Researchers simulated the trading floor in the lab by having volunteers buy and sell assets among themselves. They measured the volunteers' natural hormone levels in one experiment and artificially raised them in another. [More]
Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

A novel synthetic hormone that makes certain skin cells produce more melanin significantly increases pain-free sun exposure in people with erythropoietic protoporphyria, a rare, genetic disorder resulting in excruciating pain within minutes of sun exposure. [More]
Study demonstrates the important role of placebo effect in medical care

Study demonstrates the important role of placebo effect in medical care

The "placebo effect" is often described as events that occur when patients show improvement from treatments that contain no active ingredients. [More]
Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Avexxin AS, a therapeutic company focusing on the discovery and development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the completion of a second phase I/IIa study showing Proof-of-Concept in man. [More]
Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology. [More]
Cortisol study may explain persistence of emotional memories occurring in anxiety, PTSD

Cortisol study may explain persistence of emotional memories occurring in anxiety, PTSD

The stress hormone cortisol strengthens memories of scary experiences. However, it is effective not only while the memory is being formed for the first time, but also later when people look back at an experience while the memory reconsolidates. This has been published by cognition psychologists from the Ruhr-Universität Bochum in the journal "Neuropsychopharmacology". [More]
SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, antiemetics expert and ESMO spokesperson Fausto Roila said, putting into perspective the results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. [More]
UCSD researchers report that statins make women aggressive, but men calmer

UCSD researchers report that statins make women aggressive, but men calmer

Statins are a hugely popular drug class used to manage blood cholesterol levels and reduce the risk of heart disease. Previous studies had raised questions about adverse behavioral changes with statins, such as irritability or violence, but findings with statins have been inconsistent. In the first randomized trial to look at statin effects on behavior, researchers at the University of California, San Diego School of Medicine report that aggressive behavior typically declined among men placed on statins (compared to placebo), but typically increased among women placed on statins. [More]
ExeGi Pharma granted product license to sell Visbiome formulation in Canada

ExeGi Pharma granted product license to sell Visbiome formulation in Canada

ExeGi Pharma, a company focused on developing and commercializing live biotherapeutics and probiotic treatments, announced today that it has been granted a product license by the Health Canada Natural and Non-prescription Health Products Directorate (NNHPD) to sell Visbiome in Canada. [More]
ALS ACT initiative to speed discovery of new ALS treatments

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative. [More]
Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick and effective relief of irritable bowel syndrome (IBS) symptoms, according to clinical trial results published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD). [More]
First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections. [More]
Researchers complete participants’ enrollment in Phase III trial of vaginal ring for HIV prevention

Researchers complete participants’ enrollment in Phase III trial of vaginal ring for HIV prevention

In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing HIV in women. [More]
Egalet reports top-line results from Category 3 HAL study of Egalet-002

Egalet reports top-line results from Category 3 HAL study of Egalet-002

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
Advertisement
Advertisement